Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

U.S. Stem Cell Inc (USRM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 9,797
  • Shares Outstanding, K 368,320
  • Annual Sales, $ 5,520 K
  • Annual Income, $ -3,480 K
  • 36-Month Beta 6.30
  • Price/Sales 1.81
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 11/14/18
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0225 +12.44%
on 09/07/18
0.0299 -15.38%
on 09/18/18
-0.0009 (-3.44%)
since 08/20/18
3-Month
0.0200 +26.50%
on 08/02/18
0.0400 -36.75%
on 08/08/18
-0.0074 (-22.63%)
since 06/20/18
52-Week
0.0185 +36.76%
on 09/27/17
0.0880 -71.25%
on 04/09/18
+0.0049 (+24.02%)
since 09/20/17

Most Recent Stories

More News
USRM Hires Senior VP of US & International Sales

U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced Phil Posa has joined its executive...

USRM : 0.0253 (-4.89%)
Stem Cells Shows Promise For Repairing Torn Meniscus

USRM : 0.0253 (-4.89%)
Stem Cells Shows Promise For Repairing Torn Meniscus

U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced it has demonstrated successful,...

USRM : 0.0253 (-4.89%)
World Bodybuilding Expert Interviews USRM Chief Science Officer At Paleo F(X) Conference

U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced the release of USRM Chief Science...

USRM : 0.0253 (-4.89%)
USRM Chief Science Officer, Dr. Kristin Comella, Featured on Health Boot Camps' Webinar

U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced its Chief Science Officer,...

USRM : 0.0253 (-4.89%)
U.S. Department of Justice Files Lawsuit at Request of FDA to Stop U.S. Stem Cell Clinic from Performing Autologous Stem Cell Procedure

SUNRISE, Fla. , May 9, 2018 /PRNewswire/ -- U.S. Stem Cell, Inc. (OTC: USRM), a world leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine...

USRM : 0.0253 (-4.89%)
U.S. Stem Cell Reports First Quarter Results

SUNRISE, Fla. , May 9, 2018 /PRNewswire/ -- U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions,...

USRM : 0.0253 (-4.89%)
U.S. Stem Cell Reports First Quarter Results

U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced first quarter results for 2018....

USRM : 0.0253 (-4.89%)
USRM Chief Science Officer to Host Webinar on Autologous Stem Cell Therapy

U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced its Chief Science Officer, Dr....

USRM : 0.0253 (-4.89%)
USRM Chief Science Officer Featured in Live Interview for Biohacker Summit in Helsinki

MIAMI , May 3, 2018 /PRNewswire/ -- U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, announced...

USRM : 0.0253 (-4.89%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade USRM with:

Key Turning Points

2nd Resistance Point 0.0309
1st Resistance Point 0.0287
Last Price 0.0253
1st Support Level 0.0247
2nd Support Level 0.0229

See More

52-Week High 0.0880
Fibonacci 61.8% 0.0615
Fibonacci 50% 0.0532
Fibonacci 38.2% 0.0450
Last Price 0.0253
52-Week Low 0.0185

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar